NBIX stock forecast
Our latest prediction for Neurocrine Biosciences, Inc.'s stock price was made on the Aug. 5, 2020 when the stock price was at 118.93$.
In the short term (2weeks), NBIX's stock price should underperform the market by -0.96%. During that period the price should oscillate between -6.58% and +5.37%.
In the medium term (3months), NBIX's stock price should underperform the market by -5.08%. During that period the price should oscillate between -22.78% and +14.64%.Get email alerts
Create a solid portfolio with NBIX
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.
At the moment the company generates 1006M USD in revenues.
On its last earning announcement, the company reported a profit of 2.15$ per share.
The book value per share is 4.17$
Three months stock forecastAug. 5, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|